Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells

M. Fathy El Etreby, Yayun Liang, Robert W. Wrenn, Patricia V Schoenlein

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

MCF-7 cells growing in culture were used to study the mechanism of the antiproliferative activity of the antiprogestin mifepristone, as compared with the antiestrogen 4-hydroxytamoxifen or the combination of both. These steroid antagonists induced a significant time- and dose-dependent cell growth inhibition (cytotoxicity). This inhibition of cell survival was associated with a significant increase in DNA fragmentation (apoptosis), downregulation of bcl2, and induction of TGFβ1 protein. Abrogation of the mifepristone- and/or 4-hydroxytamoxifen-induced cytotoxicity by TGFβ1 neutralizing antibody confirms the correlation between induction of active TGFβ1 and subsequent cell death. The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFβ1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy. A translocation of protein kinase C (PKC) activity from the soluble to the particulate and/or nuclear fraction appeared to be also additive in cells treated with a combination of both 4-hydroxytamoxifen and mifepristone. These results suggest that the mechanism of the additive antiproliferative activity of mifepristone and tamoxifen could be explained at least in part by an additive induction of apoptosis in both estrogen and progesterone receptor positive MCF-7 breast cancer cells. A bcl2 downregulation, the PKC transduction pathway, and TGFβ1 expression seem to be involved in this additive mechanism of action. Our data further suggest that a combination of an antiprogestin with tamoxifen may be more effective than tamoxifen monotherapy in the management of human breast cancer.

Original languageEnglish (US)
Pages (from-to)149-168
Number of pages20
JournalBreast Cancer Research and Treatment
Volume51
Issue number2
DOIs
StatePublished - Dec 22 1998

Fingerprint

Mifepristone
Tamoxifen
Breast Neoplasms
Down-Regulation
DNA Fragmentation
Protein Kinase C
Apoptosis
Estrogen Receptor Modulators
MCF-7 Cells
Progesterone Receptors
Growth
Neutralizing Antibodies
Estrogen Receptors
Cell Survival
Proteins
Cell Death
Steroids
afimoxifene

Keywords

  • Apoptosis
  • Bcl
  • Mifepristone
  • PKC
  • Tamoxifen
  • TGFβ

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. / El Etreby, M. Fathy; Liang, Yayun; Wrenn, Robert W.; Schoenlein, Patricia V.

In: Breast Cancer Research and Treatment, Vol. 51, No. 2, 22.12.1998, p. 149-168.

Research output: Contribution to journalArticle

@article{bcbb0b1acad3465799cbfc8644d2e1fc,
title = "Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells",
abstract = "MCF-7 cells growing in culture were used to study the mechanism of the antiproliferative activity of the antiprogestin mifepristone, as compared with the antiestrogen 4-hydroxytamoxifen or the combination of both. These steroid antagonists induced a significant time- and dose-dependent cell growth inhibition (cytotoxicity). This inhibition of cell survival was associated with a significant increase in DNA fragmentation (apoptosis), downregulation of bcl2, and induction of TGFβ1 protein. Abrogation of the mifepristone- and/or 4-hydroxytamoxifen-induced cytotoxicity by TGFβ1 neutralizing antibody confirms the correlation between induction of active TGFβ1 and subsequent cell death. The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFβ1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy. A translocation of protein kinase C (PKC) activity from the soluble to the particulate and/or nuclear fraction appeared to be also additive in cells treated with a combination of both 4-hydroxytamoxifen and mifepristone. These results suggest that the mechanism of the additive antiproliferative activity of mifepristone and tamoxifen could be explained at least in part by an additive induction of apoptosis in both estrogen and progesterone receptor positive MCF-7 breast cancer cells. A bcl2 downregulation, the PKC transduction pathway, and TGFβ1 expression seem to be involved in this additive mechanism of action. Our data further suggest that a combination of an antiprogestin with tamoxifen may be more effective than tamoxifen monotherapy in the management of human breast cancer.",
keywords = "Apoptosis, Bcl, Mifepristone, PKC, Tamoxifen, TGFβ",
author = "{El Etreby}, {M. Fathy} and Yayun Liang and Wrenn, {Robert W.} and Schoenlein, {Patricia V}",
year = "1998",
month = "12",
day = "22",
doi = "10.1023/A:1006078032287",
language = "English (US)",
volume = "51",
pages = "149--168",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells

AU - El Etreby, M. Fathy

AU - Liang, Yayun

AU - Wrenn, Robert W.

AU - Schoenlein, Patricia V

PY - 1998/12/22

Y1 - 1998/12/22

N2 - MCF-7 cells growing in culture were used to study the mechanism of the antiproliferative activity of the antiprogestin mifepristone, as compared with the antiestrogen 4-hydroxytamoxifen or the combination of both. These steroid antagonists induced a significant time- and dose-dependent cell growth inhibition (cytotoxicity). This inhibition of cell survival was associated with a significant increase in DNA fragmentation (apoptosis), downregulation of bcl2, and induction of TGFβ1 protein. Abrogation of the mifepristone- and/or 4-hydroxytamoxifen-induced cytotoxicity by TGFβ1 neutralizing antibody confirms the correlation between induction of active TGFβ1 and subsequent cell death. The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFβ1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy. A translocation of protein kinase C (PKC) activity from the soluble to the particulate and/or nuclear fraction appeared to be also additive in cells treated with a combination of both 4-hydroxytamoxifen and mifepristone. These results suggest that the mechanism of the additive antiproliferative activity of mifepristone and tamoxifen could be explained at least in part by an additive induction of apoptosis in both estrogen and progesterone receptor positive MCF-7 breast cancer cells. A bcl2 downregulation, the PKC transduction pathway, and TGFβ1 expression seem to be involved in this additive mechanism of action. Our data further suggest that a combination of an antiprogestin with tamoxifen may be more effective than tamoxifen monotherapy in the management of human breast cancer.

AB - MCF-7 cells growing in culture were used to study the mechanism of the antiproliferative activity of the antiprogestin mifepristone, as compared with the antiestrogen 4-hydroxytamoxifen or the combination of both. These steroid antagonists induced a significant time- and dose-dependent cell growth inhibition (cytotoxicity). This inhibition of cell survival was associated with a significant increase in DNA fragmentation (apoptosis), downregulation of bcl2, and induction of TGFβ1 protein. Abrogation of the mifepristone- and/or 4-hydroxytamoxifen-induced cytotoxicity by TGFβ1 neutralizing antibody confirms the correlation between induction of active TGFβ1 and subsequent cell death. The effect of a combination of mifepristone and 4-hydroxytamoxifen on cell growth inhibition, on the increase in DNA fragmentation, bcl2 downregulation, and induction of TGFβ1 protein was additive and significantly different (P < 0.05) from the effect of monotherapy. A translocation of protein kinase C (PKC) activity from the soluble to the particulate and/or nuclear fraction appeared to be also additive in cells treated with a combination of both 4-hydroxytamoxifen and mifepristone. These results suggest that the mechanism of the additive antiproliferative activity of mifepristone and tamoxifen could be explained at least in part by an additive induction of apoptosis in both estrogen and progesterone receptor positive MCF-7 breast cancer cells. A bcl2 downregulation, the PKC transduction pathway, and TGFβ1 expression seem to be involved in this additive mechanism of action. Our data further suggest that a combination of an antiprogestin with tamoxifen may be more effective than tamoxifen monotherapy in the management of human breast cancer.

KW - Apoptosis

KW - Bcl

KW - Mifepristone

KW - PKC

KW - Tamoxifen

KW - TGFβ

UR - http://www.scopus.com/inward/record.url?scp=0031743456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031743456&partnerID=8YFLogxK

U2 - 10.1023/A:1006078032287

DO - 10.1023/A:1006078032287

M3 - Article

VL - 51

SP - 149

EP - 168

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -